Vivalis SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Intercell AG Approves Proposed Merger of Equals with Vivalis SA to Create Valneva SE
Vivalis SA announced that Intercell AG`s Extraordinary General Meeting (EGM) approved all resolutions, and the proposed merger of equals with Vivalis to create Valneva.
Latest Developments for Valneva SE
- Valneva SE Confirms FY 2013 Revenue Guidance in Line with Analysts' Estimates
- Valneva SE Provides Update on Phase II/III Interim Analysis of Its Pseudomonas Aeruginosa Vaccine Candidate
- Valneva SE Wins FDA Market Exclusivity for the Pediatric Indication of IXIARO in the United States
- Valneva SE Issues FY 2013 Revenue and Grants Guidance
Latest Key Developments in Biotechnology
- Share this
- Digg this